Jérôme Côté

This paper describes a pepducin derived from NTS1 that acts as a biased allosteric modulator, preferentially activating G proteins over β-arrestin and inhibiting receptor internalization.

This study shows that silencing CCR2 in sensory neurons blocks bone cancer progression and alleviates pain by disrupting neuropeptide-driven tumor growth.

The paper shows that CCR2-targeting pepducin PP101 reduces bone cancer pain by inhibiting T cell infiltration and neuroimmune communication in dorsal root ganglia without adverse effects.